The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population
Open accessAbstract
OBJECTIVES: To investigate the efficacy of once-daily oral oseltamivir for 6 weeks (Tamiflu) in prophylaxis against laboratory-confirmed clinical influenza in frail older subjects living in homes for seniors and to determine the safety and tolerability of long-term oseltamivir. DESIGN: Double-blind, placebo-controlled, parallel-group, randomized, multicenter study. SETTING: Thirty-one residential homes for seniors across United States and Europe. PARTICIPANTS: Five hundred forty-eight frail older occupants (mean age 81 years, >80% vaccinated). INTERVENTION: Prophylaxis with oseltamivir 75 mg or placebo once daily for 6 weeks, beginning when influenza was detected locally. MEASUREMENTS: The primary efficacy endpoint was laboratory-confirmed clinical influenza. RESULTS: Oseltamivir administration resulted in a 92% reduction in the incidence of laboratory-confirmed clinical influenza compared with placebo (placebo 12/272 (4.4%), oseltamivir 1/276 (0.4%); P = .002). Of subjects vaccinated against influenza, oseltamivir was 91% effective in preventing laboratory-confirmed clinical influenza (placebo 11/218 (5.0%), oseltamivir 1/222 (0.5%); P = .003). Oseltamivir use was associated with a significant reduction in the incidence of secondary complications (placebo 7/272 (2.6%), oseltamivir 1/276 (0.4%); P = .037). Although nearly all subjects were taking concomitant medication both before and during the study, oseltamivir was well tolerated. A similar incidence of adverse events, including gastrointestinal effects, occurred in both groups. There was no suppression of antibody response in oseltamivir recipients. CONCLUSION: Oral oseltamivir 75 mg once daily for 6 weeks effectively prevented clinical influenza in vaccinated frail older subjects using significant concomitant medications in a residential care setting. The treatment was well tolerated and provided additional protection to that afforded by vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Self-citationA controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
Dolin, R., Reichman, R. C., Madore, H. P., Maynard, R., Linton, P. N., & Webber-Jones, J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209023071002 · Cited by 501
Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, Jr., Elliott, M. J., & Crisp, A. (1999) · JAMA · doi:10.1001/jama.282.1.31 · Cited by 321
Cited by
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Self-citationNicholson, K. G., Wood, J. M., & Zambon, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14854-4 · Cited by 691
Metadata
- Authors
- Peters, P. H., Gravenstein, S., Norwood, P., De Bock, V., Van Couter, A., Gibbens, M., Von Planta, T., & Ward, P.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2001-08
- Volume
- 49
- Issue
- 8
- Pages
- 1025-1031
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2064631858
- Cited by
- 190
- References
- 3
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population. https://app.cochat.ai/papers/10.1046/j.1532-5415.2001.49204.x
- The paper
- Peters, P. H., Gravenstein, S., Norwood, P., De Bock, V., Van Couter, A., Gibbens, M., Von Planta, T., & Ward, P. (2001). Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population. Journal of the American Geriatrics Society. https://doi.org/10.1046/j.1532-5415.2001.49204.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.